Share this page.

Leadership and Notable Members

The Society’s membership consist of some of the top scientists in the world, who have earned many prestigious awards and professional accolades. These individuals are recognized on our Member Accomplishments page and through the SOT Awards program. SOT is governed by a 13-person elected Council with an administrative office in the Washington, DC, area.

Open All
Close All
SOT Council

2016–2017 Council

John B. Morris

University of Connecticut

Experience: Dr. Morris is a Board of Trustees Distinguished Professor at the University of Connecticut. He has been on the faculty of the Toxicology Program for 32 years and served as the director of the program from 2000–2010. He served as the head of the Pharmaceutical Sciences Department (2002–2010), assistant dean for research (2008–2013) and is currently completing his term as interim dean of the School of Pharmacy at the University. He maintains active research interests in inhalation toxicology and quantitative inhalation risk assessment and has authored approximately 90 papers and book chapters in the field. His research publications have received many awards including Faculty of 1000 recognition for being among the top 2% of publications in biomedical literature for his work on the counter-irritant effects of menthol in cigarette smoke. He served on the editorial boards of Fundamental and Applied Toxicology, Toxicological Sciences, and Inhalation Toxicology and on the TOX-2 and ALTOX-4 Study Sections for NIH. He has served on air pollutant health assessment review panels for the states of Connecticut, Vermont, and Virginia, as well as for the US Environmental Protection Agency, Centers for Disease Control Agency for Toxic Substances and Disease Registry, and the Department of Energy Office of Health and Environmental Research. He currently serves on two National Academy of Sciences panels. He is a Fellow of the Academy of Toxicological Sciences.


View John B. Morris's MyPage on ToXchange

Patricia E. Ganey
Vice President

Michigan State University

Experience: Experience: Dr. Ganey is professor of Pharmacology and Toxicology at Michigan State University. She is active in training medical and graduate students and in research. Her research focuses on understanding mechanisms by which inflammation modulates sensitivity of the liver to toxic agents and on understanding mechanisms of drug-induced liver injury. She has authored over 120 research publications in the area of toxicology, and her work has been recognized by the Faculty of 1,000. She has served on the editorial board for Toxicological Sciences and is currently on the editorial boards for Toxicology, the Journal of Toxicology and Environmental Health, and the Journal of Pharmacology and Experimental Therapeutics. She has reviewed grant applications for NIH and served as a consultant for the National Toxicology Program Office of the Report on Carcinogens. In addition to her service to SOT, Dr. Ganey has represented the interests of Toxicology by serving in the presidential chain for the Division of Toxicology of the American Society for Pharmacology and Experimental Therapeutics.


View Patricia E. Ganey's MyPage on ToXchange

Leigh Ann Burns Naas
Vice President-Elect

Gilead Sciences, Inc

Experience: Dr. Burns Naas is Vice President of Drug Safety Evaluation at Gilead Sciences, Inc. She was a Therapeutic Area Leader for Infectious Disease, Vaccines, and Oncology at Pfizer in Drug Safety research and Development over the 10 years preceding her move to Gilead. Prior to that, she worked as a product toxicologist in Health, Environmental, and regulatory Affairs at Dow Corning Corporation in Midland, Michigan. Throughout her career, her work has focused on strategic aspects and the design of safety programs to support chemical product development and registration, and to support the clinical development and licensure for small molecules and biotherapeutics, including vaccines. Dr. Burns Naas has been active in both the Society of Toxicology (SOT) and the American College of Toxicology (ACT) serving on several committees both elected and appointed in both, and serves on the Editorial Board for two journals. She has demonstrated a long commitment to promoting advancements in basic and applied toxicology, the impact of science on human and environmental health across multiple scientific organizations and in the literature, and to participating in the training/education of the next generation of toxicologists. Dr. Burns Naas received her doctorate degree in pharmacology and toxicology from the Medical College of Virginia/VCU in 1992 with an emphasis on immunotoxicology.


View Leigh Ann Burns Naas's MyPage on ToXchange

Ruth A. Roberts


Experience: Dr. Roberts is codirector and cofounder of Apconix, an integrated toxicology and ion channel company and is also adjunct professor at the University of Birmingham, United Kingdom. Before this she was global head of Regulatory Safety at AstraZeneca. She was President of EUROTOX (2012–2014), a past board member and current fellow of the Academy of Toxicological Sciences (ATS), Past President and Life Fellow of the British Toxicology Society (FBTS), a EUROTOX-Registered Toxicologist (ERT), a fellow of the Royal Society of Biology (FRSB) and a fellow of the Royal College of Pathologists (FRCPath). She chaired the 2011 Gordon Conference Cellular and Molecular Mechanisms of Toxicity and past chair (2014–2015) of the ILSI HESI Emerging Issues Committee. She has more than 20 years experience working in the forefront of international research and regulatory toxicology across pharmaceutical, agrochemical, and industrial chemical fields. Dr. Roberts is widely recognized for her expertise in cancer biology, apoptosis, preclinical strategies, and drug development. With more than 130 publications in peer-reviewed journals, Dr. Roberts received the SOT achievement award in 2002 and the EUROTOX Bo Holmstedt Award in 2008 for outstanding scientific contributions to drug and chemical safety.


View Ruth A. Roberts's MyPage on ToXchange

George P. Daston

Procter & Gamble Company

Experience: Dr. Daston is a toxicologist at Procter & Gamble, 1985–present, and is a Victor Mills Society Research Fellow; assistant professor, biology, University of Wisconsin- Milwaukee, 1983–1985; NRC Postdoctoral Fellow, US EPA (RTP), 1981–1983; adjunct professor, developmental biology and pediatrics, University of Cincinnati and Childrens Hospital Research Foundation, since 1989; President, Teratology Society, 1999–2000; Editor-in-Chief, Birth Defects Research Part B: Developmental and Reproductive Toxicology, since 2003.


View George P. Daston's MyPage on ToXchange

Michael Aschner

Albert Einstein College of Medicine

Experience: Dr. Aschner is the Harold and Muriel Block Chair and Professor at Albert Einstein College of Medicine. He has served on numerous national and international toxicology panels (Institute of Medicine, US Environmental Protection Agency, Center for Disease Control), served and chaired the Neurotoxicology and Alcohol (NAL) National Institutes of Health Study Section, and authored approximately 500 peer-reviewed manuscripts and chapters in the area of neurotoxicology. He serves as Editor (NeuroMetals) and Associate Editor (Neurotoxicology; Toxicological Science; Neurochemistry Research; Biology Trace Elements Research) and on several other editorial boards. He is a member of the Society of Toxicology (since 1986), Society for Neuroscience, a Fellow of the Academy of Toxicological Sciences, and a Past President of the International Neurotoxicology Association. In 2011, he was the recipient of the Society of Toxicology Merit Award, and in 2013 he was elected as Fellow of the American Association for the Advancement of Science (AAAS). He presently also serves as President of the International Society of Trace Elements Research in Humans. Dr. Aschner directed several large research programs including a P30 (center grant in Molecular Toxicology), the MHRP (Manganese Health Research Program, supported by the Department of Defense), and a T32 Training Grant in Molecular Toxicology.


View Michael Aschner's MyPage on ToXchange

Peter L. Goering
Past President

Silver Spring, Maryland

Experience: Dr. Goering is currently a Research Toxicologist and Lab Leader, Laboratory of Toxicology and Biocompatibility, at the US FDA, Center for Devices and Radiological Health, in Silver Spring, Maryland. He earned his PhD from the University of Kansas Medical Center, and did a postdoctoral fellowship at the NIEHS focusing on the toxicology of metals and metal defense mechanisms. At the US FDA, his research interests include nanotoxicology, evaluating liver and kidney toxic injury, elucidating new biomarkers of toxicity, and understanding mechanisms of metal toxicity. Dr. Goering has co-authored over 80 peer-reviewed publications and book chapters, is a Diplomate of the American Board of Toxicology in 1994, and was named a Fellow of Academy of Toxicological Sciences in 2006. He serves as an adjunct professor in the Toxicology Program at the University of Maryland and The George Washington University's Department of Biological Sciences. He has been active professionally in the Society of Toxicology (SOT) in several capacities. He is a member of the National Capital Area Chapter (NCAC-SOT) Regional Chapter, and served as its President in 2000–2001. He served as a Councilor (1992–1994) and President (1999–2000) of the SOT Metals Specialty Section; SOT Nominating Committee member (2004–2006); and Regulatory Affairs and Legislative Assistance Committee member (2003–2006), Chairperson from 2004–2006.


View Peter L. Goering's MyPage on ToXchange

Aaron Barchowsky

University of Pittsburgh

Experience: Dr. Barchowsky has extensive faculty experience in pharmacology, toxicology, and environmental and occupational health. He trained numerous graduate students and fellows, lectured in pharmacology and toxicology, directed core courses in medical pharmacology and in environmental health, and served on numerous graduate program committees. As director of the Environmental Health Sciences MS/PhD program in the University of Pittsburgh Graduate School of Public Health, he is active in student recruitment, curriculum development, and mentoring. After beginning his career in safety pharmacology of cardiovascular drugs, he has led a constantly active research program investigating the molecular pathogenesis of diseases caused by environmental exposures to metals. His laboratory has produced seminal work in arsenic toxicology including work recognized by the SOT 2005 Best Paper in Toxicological Sciences Award. In addition, his expertise in arsenic toxicology has been recognized through nomination and service on a number of national and international policy committees including the US EPA SAB Arsenic Committee (2005–2010), NRC Arsenic Committee (2013–2015), and WHO FERG global burden of disease committee (2011–present). He served on numerous scientific review committees for toxicology-related funding applications and is currently a standing member of the Xenobiotic and Nutrient Disposition and Action study section. He has been an associate editor of Toxicological Sciences since 2007 with special focus on metals, signal transduction, and cardiovascular toxicology.


View Aaron Barchowsky's MyPage on ToXchange

Rosonald R. Bell

Pfizer Inc., Worldwide Research and Development

Experience: Dr. Bell received his BS in biology/premedicine from Florida Agriculture and Mechanical University in Tallahassee, Florida in 1981 and his MS and PhD in pharmaceutical sciences with a concentration in pharmacology/toxicology from Florida Agriculture and Mechanical University in 1989 and 1992, respectively. In 1992, Dr. Bell accepted a two-year postdoctoral research position with The Upjohn Company (now Pfizer Inc.) in Kalamazoo, Michigan under the direction of Dr. Gerald J. Kolaja, where he was involved in nephrotoxicity method development and gained a familiarity with nonclinical drug safety assessment. In 1994, following his postdoctoral fellowship, Dr. Bell joined Ciba Pharmaceuticals Corporation (now Novartis Pharmaceuticals Corporation) in Summit, New Jersey as study director and also managed both the general and reproductive toxicology groups. He became certified in general toxicology in 1996, as a diplomate of the American Board of Toxicology. In 1998, Dr. Bell joined GD Searle/Monsanto in Skokie, Illinois and his primary role was as a Discovery and Development Project Team representative on projects in the arthritis and inflammation therapeutic area. In 2003, Dr. Bell accepted an associate research fellow position with Pfizer Inc. Dr. Bell currently serves as both a regulatory strategy lead and a drug safety team lead at Pfizer Inc., Groton, Connecticut, with the primary responsibility for Pre-FIH—LOE oversight of submissions and regulatory strategies. His responsibilities also include the design and implementation of research projects to support nonclinical safety evaluation of therapeutic agents with special emphasis on injectable anti-inflammatory biotherapeutics. His research interest is in heavy induced pulmonary toxicity with an emphasis on uncovering the biochemical and cytological alterations.


View Rosonald R. Bell's MyPage on ToXchange

Paul M. D. Foster


Experience: Dr. Foster is the Chief of the Toxicology Branch within the Division of the National Toxicology program (NTP) headquartered at the National Institute of Environmental Health Sciences (NIEHS) in Research Triangle Park, North Carolina. The Toxicology Branch is responsible for the scientific leadership of the NTP's cancer and non-cancer toxicology testing Program. Prior to joining NIEHS in 2002, he was the Director of the research program in endocrine, reproductive and developmental toxicology at the CIIT Centers for Health Research (CIIT). He joined CIIT in December 1995 after a 13-year career at Zeneca's (formerly Imperial Chemical Industries) Central Toxicology Laboratory in Cheshire, England, where he was head of Reproductive and Developmental Toxicology. He was presented with the European Society of Toxicology's young scientist award in 1988 for his work on testicular toxicity and has been awarded four NIH Merit awards and an EPA Bronze star. Dr. Foster is a Fellow of the Academy of Toxicological Sciences (ATS) and was elected to the Board of Directors in 2014 and currently serves as the Secretary/Treasurer. He serves on the editorial boards of a number of journals and is a former Associate Editor of Toxicological Sciences (1998–2005). Dr. Foster is internationally recognized for his expertise in developmental and reproductive toxicology and endocrine disruption and has served on a number of international and national (including NRC/NAS) committees in these areas of toxicology. He is the author or co-author of more than 130 peer-reviewed publications and book chapters, including 5 of the top 50 most cited papers (3 in the top 10) in Toxicological Sciences and numerous regulatory study reports.


View Paul M. D. Foster's MyPage on ToXchange

Mary Beth Genter

University of Cincinnati

Experience: Dr. Genter is a Professor in the Department of Environmental Health at the University of Cincinnati. She followed her graduate studies in neurotoxicology with a postdoctoral fellowship at the Chemical Industry Institute of Toxicology. Her first academic position was in the Department of Toxicology at North Carolina State University. Her position there included research, teaching, and service as the toxicologist for the North Carolina Cooperative Extension Service. Dr. Genter joined the Department of Environmental Health at the University of Cincinnati in 1999 and is currently a full professor. Her research interests and expertise include extrahepatic biotransformation; olfactory epithelial biology and toxic responses; and intranasal drug delivery.


View Mary Beth Genter's MyPage on ToXchange

Ofelia A. Olivero


Experience: Dr. Olivero was trained as a cytogeneticist in Argentina, and then did postdoctoral training at NIH in the National Cancer Institute. Her career continued in that organization, where she held positions of visiting associate, staff scientist, and senior staff scientist. She was able to combine her expertise in genetic toxicology with carcinogenesis. Her seminal observations on the transplacental carcinogenesis of agents used in AIDS therapy generated the field of molecular epidemiology of nucleoside analogs. She is presently applying molecular cytogenetic techniques to understand nucleoside analog induced carcinogenesis in an attempt to provide knowledge to generate safer drugs and treatments for HIV-1 patients. Dr. Olivero has generated a change in the culture of mentoring through her recent book on interdisciplinary mentoring and by delivering multiple talks and workshops on the topic. She is recognized nationally and internationally for her scientific profile and her mentoring knowledge. Additionally, she has shown a singular style of leadership based on consensus and inclusion and is currently president of the Environmental Mutagenesis and Genomics Society (formerly EMS), has been president of the Genetic Toxicology Association, and holds numerous positions in many scientific organizations. Her natural leadership, talent, and mentoring abilities together with her scientific creativity have empowered numerous young individuals to pursue careers in toxicology.


View Ofelia A. Olivero's MyPage on ToXchange

Tao Wang


Experience: Dr. Wang brings to the SOT leadership perspectives a broad range of professional experiences including clinical practice in Oncology, academic research as a NIEHS postdoctoral fellow investigating gene regulation, and professional Toxicology practice in the pharmaceutical industry supporting clinical development and licensure for small molecule and biotherapeutics. Dr. Wang is Director of Toxicology at Achaogen, Inc., where she has responsibility for all toxicology functions across early and late stage development programs, including non-clinical safety strategies, operations, resourcing, budget & timelines. Prior to joining Achaogen, Dr. Wang worked at Novartis Pharmaceuticals for more than a decade, leading safety assessment efforts for oncology and infectious disease drug development projects. During her tenure at Novartis, Dr. Wang received multiple awards, recognizing not only her significant achievements above and beyond work requirements, but also her outstanding collaboration on multidisciplinary teams. Dr. Wang has been an active member in both the SOT and American Board of Toxicology (ABT) for many years, serving on several committees both elected and appointed. She also serves on the Editorial Board for International Journal of Toxicology and Toxicology Research and Application. Dr. Wang remains active in the research community, publishing results of her research in peer-reviewed journals. Dr. Wang also teaches in Practical Toxicology course at the University of California at Berkeley as a guest lecturer. She has demonstrated a long-standing commitment to promoting advancements in basic and applied toxicology, and a passion to participate in the training/education of the next generation of toxicologists.


View Tao Wang's MyPage on ToXchange

Clarissa L. Russell
Executive Director

Experience: Ms. Russell Wilson has been Deputy Director for the Society of Toxicology since 1996. In addition, she has been Senior Vice President, Association Innovation and Management (AIM), an association management company providing administrative services to the toxicology community, since the inception of the company in 1999. Ms. Russell Wilson has earned a Master in Business Administration with a concentration in finance from Johns Hopkins University. Along with earning her undergraduate degree from James Madison University and she also earned a culinary degree from the École hôtelière de Lausanne in conjunction with the University of Nevada, Las Vegas.


View Clarissa L. Russell's MyPage on ToXchange

Elected and Appointed Committees
The Society’s activities are highly diverse and assisted by the efforts of more than 40 Elected and Appointed Committees, Subcommittees, and Task Forces. All of these groups support the Society’s mission and further the objectives of its Strategic Plan.

Go to: The complete list of Elected and Appointed Committees and their members

Past Presidents
During its history, the Society has been guided by more than 50 exemplary toxicologists and leaders.

Go to: The complete list of SOT Past Presidents

25-Plus-Year Members
The Society of Toxicology appreciates the loyalty and contributions of the members who have grown with the Society, and we are honored to recognize those members who have been with us for more than 25 years.

Go to: The complete list of 25-plus-year SOT Members

Charter Members
The 108 Charter Members of the Society are those members who joined the Society in its first year from March 4, 1961, to March 4, 1962.

Go to: The complete list of SOT Charter Members

Emeritus Members
Emeritus Members of the Society are those members who have maintained membership continuously for 40 years. The Society currently includes more than 275 Emeritus Members.

Go to: The complete list of SOT Emeritus Members

Member Accomplishments
SOT members have been the recipients of prestigious national and international honors from the scientific community, and we honor them for these accomplishments.

Go to: A list of national and international awards received by SOT Members

In Memoriam
The Society mourns the dear friends who have passed away in the last 18 months.

Go to: A list of recently deceased SOT Members